Clinical Trial Update: Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

An ongoing Phase 4 trial assessing the safety and efficacy of varenicline (CHANTIX) for smoking cessation in patients with acute coronary syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Tobacco Use Disorder

Drugs mentioned

• CHANTIX (varenicline tartrate)

Snippet

Sponsor: Newark Beth Israel Medical Center | Conditions: Smoking, Acute Coronary Syndrome | Phase 4 | Status: UNKNOWN